
Sign up to save your podcasts
Or


In this episode of Hybrid Healing Hour, we sit down with Dr. Michael Hafran, Regional Medical Director of Flourish Research in Boca Raton, for an in-depth conversation on the future of cardiovascular medicine: gene editing for high cholesterol.
Dr. Hafran takes us inside the groundbreaking VERVE-102 clinical trial, developed by Verve Therapeutics, which aims to transform how we treat familial hypercholesterolemia (FH) and severe LDL elevation. Rather than relying solely on lifelong medications to manage cholesterol levels, this investigational therapy explores the possibility of rewriting genetic instructions that drive elevated LDL at its source.
Key Points Discussed:
🧬 The Pathophysiology of Cholesterol
We break down how LDL cholesterol contributes to atherosclerosis, plaque formation, and cardiovascular risk — and why some individuals are genetically predisposed to dangerously high levels from birth.
🧬 Understanding Familial Hypercholesterolemia (FH)
Dr. Hafran explains the genetic mutations behind FH, how it differs from lifestyle-related hypercholesterolemia, and why early diagnosis is critical.
💊 From Managing Disease to Rewriting Instructions
Traditional treatments like statins, PCSK9 inhibitors, and lifestyle interventions focus on management. The VERVE-102 trial represents a paradigm shift: a single-course gene editing therapy designed to permanently reduce LDL by modifying the PCSK9 pathway at the DNA level.
⚖️ Safety, Ethics & Long-Term Considerations
We explore the big questions:
What are the potential off-target effects?
How do researchers evaluate long-term safety in gene editing?
What ethical considerations arise when altering genetic code?
How do the risks of untreated FH compare to the risks of gene editing?
🔬 Risk vs. Benefit: A New Era in Preventive Cardiology
Dr. Hafran offers insight into how clinicians weigh the lifelong cardiovascular burden of FH against the promise of a potentially one-time genetic intervention.
This episode is a compelling deep dive into precision medicine, prevention, and the evolving science of cardiovascular genetics. Whether you're a healthcare professional, researcher, or someone personally affected by high cholesterol, this conversation sheds light on what may become one of the most transformative advances in heart disease prevention.
Flourish Research Info:
Website: https://flourishresearch.com/locations/boca-raton/
Phone #: (561) 513-6266 (ask for Johanna)
Address: 7900 Glades Rd #400, Boca Raton, FL 33434
Facebook: Hybrid Medical Solution
Instagram: @hybrid_medical_solution
Website : www.hybridmedicalsolution.com
YouTube: @HybridMedicalSolution
By Deanna Weilbacher5
1616 ratings
In this episode of Hybrid Healing Hour, we sit down with Dr. Michael Hafran, Regional Medical Director of Flourish Research in Boca Raton, for an in-depth conversation on the future of cardiovascular medicine: gene editing for high cholesterol.
Dr. Hafran takes us inside the groundbreaking VERVE-102 clinical trial, developed by Verve Therapeutics, which aims to transform how we treat familial hypercholesterolemia (FH) and severe LDL elevation. Rather than relying solely on lifelong medications to manage cholesterol levels, this investigational therapy explores the possibility of rewriting genetic instructions that drive elevated LDL at its source.
Key Points Discussed:
🧬 The Pathophysiology of Cholesterol
We break down how LDL cholesterol contributes to atherosclerosis, plaque formation, and cardiovascular risk — and why some individuals are genetically predisposed to dangerously high levels from birth.
🧬 Understanding Familial Hypercholesterolemia (FH)
Dr. Hafran explains the genetic mutations behind FH, how it differs from lifestyle-related hypercholesterolemia, and why early diagnosis is critical.
💊 From Managing Disease to Rewriting Instructions
Traditional treatments like statins, PCSK9 inhibitors, and lifestyle interventions focus on management. The VERVE-102 trial represents a paradigm shift: a single-course gene editing therapy designed to permanently reduce LDL by modifying the PCSK9 pathway at the DNA level.
⚖️ Safety, Ethics & Long-Term Considerations
We explore the big questions:
What are the potential off-target effects?
How do researchers evaluate long-term safety in gene editing?
What ethical considerations arise when altering genetic code?
How do the risks of untreated FH compare to the risks of gene editing?
🔬 Risk vs. Benefit: A New Era in Preventive Cardiology
Dr. Hafran offers insight into how clinicians weigh the lifelong cardiovascular burden of FH against the promise of a potentially one-time genetic intervention.
This episode is a compelling deep dive into precision medicine, prevention, and the evolving science of cardiovascular genetics. Whether you're a healthcare professional, researcher, or someone personally affected by high cholesterol, this conversation sheds light on what may become one of the most transformative advances in heart disease prevention.
Flourish Research Info:
Website: https://flourishresearch.com/locations/boca-raton/
Phone #: (561) 513-6266 (ask for Johanna)
Address: 7900 Glades Rd #400, Boca Raton, FL 33434
Facebook: Hybrid Medical Solution
Instagram: @hybrid_medical_solution
Website : www.hybridmedicalsolution.com
YouTube: @HybridMedicalSolution

229,564 Listeners

28,085 Listeners

7,980 Listeners

11,320 Listeners